Clinical Trial: A Controlled Study of Uric Acid on the Progression of IgA Nephropathy

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: A Prospective, Randomized Controlled Study of Uric Acid on the Progression of IgA Nephropathy

Brief Summary: This prospective, randomized controlled study will evaluate the effect of uric acid on the progression of IgA nephropathy.

Detailed Summary: It has been reported that hyperuricemia is a risk factor for progression of IgAN. This will be a prospective, randomized study. Eligible IgAN patients will be randomized into the treatment group and the control group. Patients in treatment group will receive allopurinol and usual therapy. Patients in control group will receive usual therapy with placebo. If with hypertension, add the CCB and the β-blocker. Fasting uric acid, serum creatinine, albumin, routine blood test, urine microscopy and dipstick, proteinuria of 24 hours and blood pressure will be measured every month. After followed-up for 6 months, the curative effect of Allopurinol on blood pressure, proteinuria and the progression of IgA nephropathy will be evaluated.
Sponsor: Sun Yat-sen University

Current Primary Outcome: Change in Renal Function as Measured With eGFR [ Time Frame: baseline and 6 months ]

Original Primary Outcome: The longitudinal change in glomerular filtration rate (GFR)and fasting serum uric acid [ Time Frame: Every month ]

Current Secondary Outcome: The Longitudinal Change in Proteinuria and Blood Pressure(Including Changes in Antihypertensive Drugs Dosing). [ Time Frame: baseline and 6 months ]

Original Secondary Outcome: The longitudinal change in serum creatinine, proteinuria and blood pressure. [ Time Frame: Every month ]

Information By: Sun Yat-sen University

Dates:
Date Received: November 17, 2008
Date Started: July 2007
Date Completion:
Last Updated: April 25, 2016
Last Verified: April 2016